RemeGen Co., Ltd. (HKG: 9995)
Hong Kong
· Delayed Price · Currency is HKD
13.48
-0.92 (-6.39%)
Jan 2, 2025, 4:08 PM HKT
RemeGen Revenue
RemeGen had revenue of 467.12M CNY in the quarter ending September 30, 2024, with 34.60% growth. This brings the company's revenue in the last twelve months to 1.52B, up 56.63% year-over-year. In the year 2023, RemeGen had annual revenue of 1.08B with 40.26% growth.
Revenue (ttm)
1.52B CNY
Revenue Growth
+56.63%
P/S Ratio
4.19
Revenue / Employee
421.12K CNY
Employees
3,615
Market Cap
12.97B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 26.04B |
Hansoh Pharmaceutical Group Company | 13.00B |
JD Health International | 58.84B |
WuXi Biologics | 18.39B |
Sinopharm Group | 634.32B |
Innovent Biologics | 8.01B |
Sino Biopharmaceutical | 29.86B |
CSPC Pharmaceutical Group | 33.53B |